Major Breakthrough by Prof. Ashis Biswas (Dept. of Chemistry, SBS): IIT Bhubaneswar and ILS Transfer Next-Gen TB Vaccine Technology for Clinical Trials
We are delighted to announce a significant achievement in vaccine technology development by Prof. Ashis Biswas from the Department of Chemistry, School of Basic Sciences (SBS), IIT Bhubaneswar, in collaboration with Dr. Sunil K. Raghav from the Institute of Life Sciences (ILS), Bhubaneswar.
The Achievement: A Novel TB Vaccine (HSP-163-DC4)
The joint research effort has successfully developed a Next-Generation Tuberculosis (TB) Vaccine Technology known as HSP-163-DC4. This novel vaccine holds immense promise in the global fight against Tuberculosis, a disease that continues to be a major public health challenge.
Technology Transfer and Clinical Trials
The innovative technology has been officially transferred to TechInvention Lifecare Ltd., a leading organization dedicated to making advanced healthcare solutions accessible. This successful transfer marks a critical step towards large-scale production and accessibility.
Crucially, the next phase will involve the commencement of Clinical Trials for this vaccine very soon. This milestone signifies the transition of laboratory research into a real-world solution poised to save lives.
The salient features and mechanism of action of this newly developed TB vaccine are further elucidated in the accompanying visual aid provided by Prof. Biswas (the attached picture).
For more details on this groundbreaking collaboration and technology transfer, please visit the following links: